Medlive Technology Co., Ltd.

SEHK:2192 Stok Raporu

Piyasa değeri: HK$6.2b

Medlive Technology Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Medlive Technology is forecast to grow earnings and revenue by 7.7% and 16.2% per annum respectively. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be 5.9% in 3 years.

Anahtar bilgiler

7.7%

Kazanç büyüme oranı

6.1%

EPS büyüme oranı

Healthcare Services kazanç büyümesi32.5%
Gelir büyüme oranı16.2%
Gelecekteki özkaynak getirisi5.9%
Analist kapsamı

Low

Son güncelleme29 Aug 2024

Gelecekteki son büyüme güncellemeleri

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Oct 02
Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Sep 27
Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 04
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Apr 08
Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Feb 20
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Jan 10
Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 27
Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Jul 10
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

May 11
Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

May 02
Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

Feb 06
Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Oct 31
There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 14
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Apr 03
These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Feb 22
Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Kazanç ve Gelir Büyüme Tahminleri

SEHK:2192 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026834363N/A2303
12/31/2025689317N/A1683
12/31/2024537274N/A1113
6/30/20244822905792N/A
3/31/20244472666397N/A
12/31/202341224269102N/A
9/30/20233842166990N/A
6/30/20233561896979N/A
3/31/20233351536978N/A
12/31/20223141177077N/A
9/30/2022300835157N/A
6/30/2022286483236N/A
3/31/2022285443740N/A
12/31/2021284414244N/A
9/30/2021270557173N/A
6/30/202125570100101N/A
3/31/202123478105106N/A
12/31/202021485110111N/A
12/31/2019122312628N/A
12/31/201883141922N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 2192's forecast earnings growth (7.7% per year) is above the savings rate (2.3%).

Kazançlar ve Piyasa: 2192's earnings (7.7% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).

Yüksek Büyüme Kazançları: 2192's earnings are forecast to grow, but not significantly.

Gelir ve Pazar: 2192's revenue (16.2% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Yüksek Büyüme Geliri: 2192's revenue (16.2% per year) is forecast to grow slower than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 2192's Return on Equity is forecast to be low in 3 years time (5.9%).


Büyüyen şirketleri keşfedin